Fresenius SE & Co. KGaA sold 13.4 million shares in Fresenius Medical Care for about €524 million gross, leaving a stake of about 20%, with net proceeds intended to support growth investment.
Fresenius completed the sale on Nov. 12 at €39 a share. Its share of issued capital fell from about 25% to roughly 20%; retained shares cannot be sold for 90 days except under customary exceptions.
The roughly 20% estimate could change if bonds are exchanged for Fresenius Medical Care shares or if shares are canceled through Fresenius Medical Care's current buyback program.
Since Fresenius Medical Care's deconsolidation on Nov. 30, 2023, Fresenius' holding has declined from about 32%, while gross proceeds from sales have totaled about €2.3 billion. Chief Financial Officer Sara Hennicken said the sale advances Fresenius' #FutureFresenius capital-allocation priorities and supports investment and strategy in what she called the “REJUVENATE phase.”
Fresenius expects the sale to lift book profit by a low-to-mid double-digit amount in millions of euros. It plans to classify the gain separately as a special item in its results for the final quarter of 2026. Settlement is expected Monday, Nov. 16.
